Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study

NCT07516704 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT07516704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07516704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Lead sponsor
Zhongda Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
December 12, 2027
Enrollment
94 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer